9.47 USD
↘ 0.40 (4.05%)AT CLOSE (11:59 AM EDT)
Replimune Group, Inc.
REPLNASDAQ • USD
9.47
↘ 0.01 (0.05%)
POST MARKET (AS OF 07:53 PM EDT)
Post Market
AS OF 07:53 PM EDT
9.47
↘ 0.01 (0.05%)
Market: CLOSED
Open?$9.98
High?$10.46
Low?$9.39
Prev. Close?$9.87
Volume?4.6M
Avg. Volume?8.0M
VWAP?$9.87
Rel. Volume?0.58x
Bid / Ask
Bid?$9.42 × 100
Ask?$9.59 × 600
Spread?$0.17
Midpoint?$9.50
Valuation & Ratios
Market Cap?782.0M
Shares Out?82.6M
Float?59.2M
Float %?71.7%
P/E Ratio?N/A
P/B Ratio?3.71
EPS?-$3.81
Dividend?0.00%
Ex-Dividend?N/A
REPL is currently priced at $9.47. REPL shows a split signal: technical indicators suggest "Buy" while underlying fundamentals indicate "Sell". This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity and a bearish Death Cross on the long-term moving averages. On valuation, REPL trades roughly in line with sector averages — neither particularly cheap nor expensive.
Technical & fundamental data as of Jun 5, 2026.
News
Profile
Replimune Group Inc is a clinical-stage biotechnology company. It uses a proprietary RPx platform to design and develop product candidates that are intended to maximally activate the immune system against solid tumors. The RPx platform is based on a proprietary, engineered strain of herpes simplex virus 1, or HSV-1, backbone with payloads added to maximize immunogenic cell death and the induction of a systemic anti-tumor immune response. The company focuses on developing oncolytic immunotherapies for the treatment of cancer. Its pipeline products include RP1, RP2, and RP3. The company operates in USA and UK, majority of revenue from USA.
Employees
479
Market Cap
782.0M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Website
Listed
2018-07-20
Address
500 UNICORN PARK
WOBURN, MA 01801
Phone: (781) 222-9600
WOBURN, MA 01801
Phone: (781) 222-9600
Technical OutlookBuy
Strong SellNeutralStrong Buy
Long-Term (Tide)?▲ Bullish(+1/3)
Medium-Term (Wave)?▲ Bullish(+2/3)
Short-Term (Ripple)?– Neutral(0/3)
MA Alignment?Mixed
Full Technical Analysis →Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?3
Z-Score?0
Momentum?50
Short Sent.?44
Piotroski F-Score?0/9Weak
Altman Z-Score?-3.57Distress
Confidence?56%Low
Short InterestSqueeze Risk
Short % of Float?39.97%Squeeze Risk
Short Interest?23.7M
Days to Cover?2.8
Free Float59.2M
Avg Daily Volume8.4M
Settlement Date2026-05-15
Financial Health
Current Ratio?5.60Strong
Quick Ratio?5.60Strong
Cash Ratio?2.45Strong
Debt/Equity?0.34Low
ValuationATTRACTIVELY VALUEDvs 1 peers + S&P 500
Score83/100
P/E?N/A▾
P/B?3.71FAIR▾
Peers100
S&P47
P/S?N/A▾
P/FCF?N/A▾
EV/EBITDA?-2.3CHEAP▾
S&P97
EV/Sales?N/A▾
Returns & Efficiency
ROE?-149.6%WEAK▾
S&P3
ROA?-94.4%WEAK▾
S&P3
Cash Flow & Enterprise
FCF?$-283266000
Enterprise Value?$731.6M
Fundamentals ratios updated end of day